Severe Asthma in the Era of Biologics: Continuous Challenges
暂无分享,去创建一个
[1] F. Menzella. Baseline Characteristics of Patients Enrolled in Clinical Trials of Biologics for Severe Asthma as Potential Predictors of Outcomes , 2023, Journal of clinical medicine.
[2] M. D’Amato,et al. Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting , 2023, Journal of clinical medicine.
[3] E. Bargagli,et al. High Level of Blood Eosinophils and Localization of Bronchiectasis in Patients with Severe Asthma: A Pilot Study , 2023, Journal of clinical medicine.
[4] C. Kyriakopoulos,et al. Can Leukotriene Receptor Antagonist Therapy Improve the Control of Patients with Severe Asthma on Biological Therapy and Coexisting Bronchiectasis? A Pilot Study , 2022, Journal of clinical medicine.
[5] W. Hung,et al. The Long-Term Effectiveness of Omalizumab in Adult Patients with Severe Allergic Asthma: Continuous Treatment Versus Boosting Treatment , 2021, Journal of clinical medicine.
[6] S. Loukides,et al. Severe Eosinophilic Asthma , 2019, Journal of clinical medicine.